TREATMENT WITH PCSK9 INHIBITORS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA LOWERS PLASMA LEVELS OF PLATELET ACTIVATING FACTOR AND ITS PRECURSORS: A COMBINED METABOLOMIC AND LIPIDOMIC APPROACH

被引：0

作者：

Di Minno, A. ^{[1
]}

Calcaterra, I. L. ^{[2
]}

Orsini, R. ^{[2
]}

Chiesa, M. ^{[3
,4
]}

Cavalca, V. ^{[5
]}

Anesi, A. ^{[6
]}

Fiorelli, S. ^{[5
]}

Eligini, S. ^{[5
]}

Colombo, G. ^{[5
]}

Donnarumma, S. ^{[2
]}

Palermo, V. ^{[2
]}

Tremoli, E. ^{[5
]}

Porro, B. ^{[5
]}

Di Minno, M. N. D. ^{[2
]}

机构：

[1] Univ Naples Federico II, Pharm, Naplesa, Italy

[2] Univ Naples Federico II, Dept Clin Med & Surg, Naples, Italy

[3] Ctr Cardiol Monzino, Unit Study Aort Valvular & Coronary Pathol, Milan, Italy

[4] Ctr Cardiol Monzino, Bioinformat & Artificial Intelligence Facil, Milan, Italy

[5] Metabol Unit, Centro cardiologico monzino, Milan, Italy

[6] Ondazione Edmund Mach Res & Innovat Ctr, Food Qual & Nutr, San Michele All Adige, Italy

来源：

ATHEROSCLEROSIS | 2023年 / 379卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P202

引用

页码：S63 / S64

页数：2

共 5 条

[1] Treatment with PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia Lowers Plasma Levels of Platelet-Activating Factor and Its Precursors: A Combined Metabolomic and Lipidomic Approach
Di Minno, Alessandro
Orsini, Roberta Clara
Chiesa, Mattia
Cavalca, Viviana
Calcaterra, Ilenia
Tripaldella, Maria
Anesi, Andrea
Fiorelli, Susanna
Eligini, Sonia
Colombo, Gualtiero, I
Tremoli, Elena
Porro, Benedetta
Di Minno, Matteo Nicola Dario
BIOMEDICINES, 2021, 9 (08)
[2] APPROACH OF THERAPEUTICS GOALS IN A GROUP OF PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA UNDER PCSK9 INHIBITORS TREATMENT
Puente, A. C.
Olivares, P. I.
Trujillo, R.
ATHEROSCLEROSIS, 2022, 355 : E231 - E231
[3] No effect of PCSK9 inhibitors on D-dimer and fibrinogen levels in patients with familial hypercholesterolemia
Schol-Gelok, Suzanne
Galema-Boers, J. M. H.
van Gelder, Teun
Kruip, Marieke J. H. A.
van Lennep, Jeanine E. Roeters
Versmissen, Jorie
BIOMEDICINE & PHARMACOTHERAPY, 2018, 108 : 1412 - 1414
[4] Persistence to long-term PCSK9 inhibitors treatment and its effectiveness in familial hypercholesterolemia: data from the SAFEHEART study
Alonso, R.
Arroyo-Olivares, R.
Muniz-Grijalvo, O.
Diaz-Diaz, J. L.
Munoz-Torrero, J. Sanchez
Zambon, D.
Fuentes-Jimenez, F.
Romero, M. J.
Aguado, R.
Alvarez-Banos, P.
Manas, M. D.
Arrieta, F.
Gonzalez-Bustos, P.
Argueso, R.
Mata, P.
EUROPEAN HEART JOURNAL, 2022, 43 : 2372 - 2372
[5] PCSK9 INHIBITORS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA AND/OR CVD: THE IMPACT OF A SYSTEMATIC, TEAM-BASED APPROACH TO PRESCRIPTION ON RATES OF INSURANCE APPROVAL AND LIPID LOWERING
Knickelbine, Thomas
Garberich, Ross
White, Susan
Oberembt, Sandra
Wills, Samantha
Miedema, Michael
Brilakis, Emmanouil
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 1728 - 1728

← 1 →